MCID: HRN003
MIFTS: 43

Heroin Dependence

Categories: Mental diseases

Aliases & Classifications for Heroin Dependence

MalaCards integrated aliases for Heroin Dependence:

Name: Heroin Dependence 12 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9976
MeSH 41 D006556
NCIt 46 C34694
UMLS 69 C0019337

Summaries for Heroin Dependence

Disease Ontology : 12 An opiate dependence that involves the continued use of heroin despite problems related to use of the substance.

MalaCards based summary : Heroin Dependence is related to personality disorder and antisocial personality disorder. An important gene associated with Heroin Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Amphetamine addiction. The drugs Dopamine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Heroin Dependence

Diseases related to Heroin Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 personality disorder 30.0 BDNF DRD2 DRD4 SLC6A3
2 antisocial personality disorder 29.9 ANKK1 DRD2 SLC6A3
3 morphine dependence 29.9 OPRD1 OPRM1
4 major depressive disorder 29.2 BDNF DRD2 DRD4 SLC6A3
5 autism 29.0 AUTS2 BDNF DRD2 DRD4
6 schizophrenia 28.8 BDNF DRD2 DRD4 GABRB2 SLC6A3
7 attention deficit-hyperactivity disorder 28.6 ANKK1 BDNF DRD2 DRD4 SLC6A3
8 substance dependence 28.4 BDNF DRD2 DRD4 OPRD1 OPRM1 SLC6A3
9 cocaine dependence 28.3 DRD2 OPRD1 OPRM1 PDYN SLC6A3
10 disease of mental health 28.0 BDNF DRD2 DRD4 OPRM1 PDYN SLC6A3
11 alcohol-induced mental disorder 10.3 DRD2 SLC6A3
12 alcoholic psychosis 10.3 DRD2 SLC6A3
13 striatonigral degeneration 10.3 DRD2 SLC6A3
14 delusional disorder 10.3 DRD2 DRD4
15 traumatic brain injury 10.3 BDNF DRD2
16 neonatal abstinence syndrome 10.3 OPRD1 OPRM1
17 separation anxiety disorder 10.2 DRD4 SLC6A3
18 cocaine abuse 10.2 DRD2 SLC6A3
19 brain injury 10.2 BDNF DRD2
20 migraine without aura 10.2 DRD2 DRD4
21 stuttering 10.1 DRD2 SLC6A3
22 taqi polymorphism 10.1 ANKK1 DRD2
23 eating disorder 10.1 BDNF DRD2 SLC6A3
24 alexithymia 10.1 ANKK1 DRD2
25 opioid addiction 10.1 DRD2 OPRD1 OPRM1
26 early-onset schizophrenia 10.1 BDNF DRD2 DRD4
27 pathological gambling 10.1 DRD2 DRD4 SLC6A3
28 oppositional defiant disorder 10.1 DRD2 DRD4 SLC6A3
29 multiple system atrophy 1 10.1 DRD2 SLC6A3
30 tic disorder 10.1 DRD2 DRD4 SLC6A3
31 mood disorder 10.1 BDNF DRD2 DRD4
32 conduct disorder 10.1 DRD2 DRD4 SLC6A3
33 orofacial cleft 10.0 DRD2 DRD4 SLC6A3
34 migraine with or without aura 1 10.0 DRD2 DRD4 SLC6A3
35 generalized anxiety disorder 10.0 BDNF DRD2
36 withdrawal disorder 10.0 OPRM1 PDYN
37 hepatitis 10.0
38 borderline personality disorder 10.0
39 pain agnosia 9.9 OPRM1 PDYN
40 aging 9.9
41 impulse control disorder 9.9 ANKK1 DRD2 DRD4
42 agnosia 9.9 OPRM1 PDYN
43 amnestic disorder 9.9 BDNF PDYN
44 substance abuse 9.8 BDNF DRD2 DRD4 SLC6A3
45 gilles de la tourette syndrome 9.8 BDNF DRD2 DRD4 SLC6A3
46 opioid abuse 9.8 DRD2 OPRM1 PDYN
47 psychotic disorder 9.8 BDNF DRD2 DRD4 SLC6A3
48 obsessive-compulsive disorder 9.8 BDNF DRD2 DRD4 SLC6A3
49 hepatitis c virus 9.8
50 episodic pain syndrome, familial, 1 9.8

Graphical network of the top 20 diseases related to Heroin Dependence:



Diseases related to Heroin Dependence

Symptoms & Phenotypes for Heroin Dependence

MGI Mouse Phenotypes related to Heroin Dependence:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 AUTS2 PDYN BDNF SLC6A3 DRD2 DRD4
2 homeostasis/metabolism MP:0005376 9.92 OPRM1 PDYN BDNF SLC6A3 DRD2 DRD4
3 nervous system MP:0003631 9.76 OPRM1 PDYN BDNF SLC6A3 DRD2 DRD4
4 integument MP:0010771 9.73 OPRM1 PDYN BDNF SLC6A3 DRD2 OPRD1
5 no phenotypic analysis MP:0003012 9.43 OPRM1 AUTS2 PDYN BDNF DRD2 OPRD1
6 taste/olfaction MP:0005394 8.8 BDNF SLC6A3 DRD2

Drugs & Therapeutics for Heroin Dependence

Drugs for Heroin Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Heroin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1 561-27-3 5462328
3
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1 76-99-3 4095
4
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 644073 40400
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 93-14-1 3516
6
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
7
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 465-65-6 5284596
8
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
9
Serotonin Phase 4,Phase 3 50-67-9 5202
10 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
11 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
13 Serotonin Agents Phase 4,Phase 3
14 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 2,Phase 3,Phase 1
15 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
16 Narcotics Phase 4,Phase 2,Phase 3,Phase 1
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Tranquilizing Agents Phase 4,Phase 3,Phase 1
19 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
20 Opiate Alkaloids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Psychotropic Drugs Phase 4,Phase 3,Phase 1
24 Antitussive Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Anti-Anxiety Agents Phase 4
26 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1
27
Morphine Approved, Investigational Phase 3,Phase 2,Phase 1 57-27-2 5288826
28
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
29
Mianserin Approved, Investigational Phase 3 24219-97-4 4184
30
Amphetamine Approved, Illicit, Investigational Phase 3,Phase 1 300-62-9 3007 5826
31
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
32
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
33
Clonidine Approved Phase 3,Phase 1 4205-90-7 2803
34
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
35
Hydromorphone Approved, Illicit Phase 3,Phase 2,Phase 1 466-99-9 5284570
36
Imidacloprid Vet_approved Phase 2, Phase 3 105827-78-9 86418
37
Histamine Phosphate Phase 3 51-74-1 65513
38 Adrenergic Agents Phase 3,Phase 2,Phase 1
39 Central Nervous System Stimulants Phase 3,Phase 1,Phase 2
40 Serotonin 5-HT2 Receptor Antagonists Phase 3
41 Serotonin Antagonists Phase 3
42 Adrenergic alpha-Antagonists Phase 3,Phase 1
43 Adrenergic Antagonists Phase 3,Phase 1
44 Neurotransmitter Uptake Inhibitors Phase 3,Phase 2,Phase 1
45 Histamine Antagonists Phase 3
46 Histamine H1 Antagonists Phase 3
47 Paliperidone Palmitate Phase 3
48 Dopamine Antagonists Phase 3
49 Dopamine D2 Receptor Antagonists Phase 3
50 Dopamine Uptake Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 90)

# Name Status NCT ID Phase Drugs
1 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
2 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
3 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4 Buspirone
5 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
6 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
7 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
8 Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
9 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541513 Phase 3 paliparidone
10 An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541500 Phase 3 Minocycline
11 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Completed NCT00476242 Phase 2, Phase 3 Vivitrol;memantine
12 Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Completed NCT01760473 Phase 3 Intranasal challenge drug
13 Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Completed NCT00577408 Phase 3 depot naltrexone;Oral Naltrexone
14 Study Comparing Liquid and Tablet Buprenorphine Formulations - 5 Completed NCT00000302 Phase 3 Buprenorphine
15 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial Completed NCT00684554 Phase 2, Phase 3 Buprenorphine
16 Directly Administered HIV Therapy in Methadone Clinics Completed NCT00279110 Phase 2, Phase 3
17 Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Completed NCT01447212 Phase 3 Hydromorphone, Injectable;Diacetylmorphine, injectable;Hydromorphone, liquid oral;Diacetylmorphine, liquid oral
18 Buprenorphine for Prisoners Completed NCT00574067 Phase 3 Buprenorphine +OTP;Buprenorphine +CHC;Counseling +OTP;Counseling +CHC
19 Methadone Maintenance for Prisoners Completed NCT00378079 Phase 3 Counseling + Transfer;Counseling + Methadone
20 Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Completed NCT00015171 Phase 3 Buprenorphine/naloxone
21 Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Completed NCT00032968 Phase 3 Buprenorphine/naloxone
22 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Completed NCT00032955 Phase 3 Buprenorphine/naloxone
23 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
24 ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence Completed NCT00678418 Phase 3 VIVITROL® 380 mg;Placebo
25 The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention Recruiting NCT02440152 Phase 2, Phase 3
26 Addiction Treatment in Russia: Oral vs. Naltrexone Implant Active, not recruiting NCT00218426 Phase 2, Phase 3 naltrexone implant;Oral naltrexone;placebo oral and placebo implant
27 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
28 Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India Withdrawn NCT00709007 Phase 2, Phase 3
29 Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
30 Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1 Unknown status NCT00023283 Phase 2 Buprenorphine
31 Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Completed NCT00218127 Phase 2 Levoacetyl Methadol;Levoacetyl Methadol;Levoacetyl Methadol
32 Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Completed NCT00332228 Phase 2 depot naltrexone;BNT
33 Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts Completed NCT00142948 Phase 2 Naltrexone;Placebo
34 A Laboratory Model for Heroin Abuse Medications - 8 Completed NCT00000273 Phase 2 opiates
35 Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Completed NCT00238914 Phase 2 Naltrexone
36 Effects of Dynorphin 1-13 on Heroin Addiction - 1 Completed NCT00000244 Phase 2 Dynorphin 1 - 13
37 Study of Computer-Based Treatment for Drug Dependence Completed NCT01315184 Phase 2
38 Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals Completed NCT00218309 Phase 2 Hydromorphone
39 Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Completed NCT00000211 Phase 2 Buprenorphine
40 Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Completed NCT00000210 Phase 2 Buprenorphine
41 Addition of Naltrexone to Methadone Taper Completed NCT00135759 Phase 2 Naltrexone;Placebo comparator;naltrexone;naltrexone
42 Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia Completed NCT01863251 Phase 2 Atomoxetine
43 Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone Completed NCT02046252 Phase 2 Oral naltrexone;Naltrexone implant
44 The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 Completed NCT00158288 Phase 2
45 Pioglitazone for Heroin and for Nicotine Dependence Terminated NCT01395797 Phase 1, Phase 2 PIO;Placebo
46 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1 Withdrawn NCT00000326 Phase 2 Heroin Dependence
47 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2 Withdrawn NCT00000327 Phase 2 Heroin Dependence
48 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6 Withdrawn NCT00000331 Phase 2 Test Drug;Placebo Drug
49 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Withdrawn NCT00000330 Phase 2 Opioid-Related Disorders
50 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4 Withdrawn NCT00000329 Phase 2 Opioid-Related Disorders

Search NIH Clinical Center for Heroin Dependence

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: heroin dependence

Genetic Tests for Heroin Dependence

Anatomical Context for Heroin Dependence

MalaCards organs/tissues related to Heroin Dependence:

38
Brain, Testes, Pituitary

Publications for Heroin Dependence

Articles related to Heroin Dependence:

(show top 50) (show all 234)
# Title Authors Year
1
Neural Correlates of Drug-Related Attentional Bias in Heroin Dependence. ( 29410620 )
2017
2
Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. ( 28371689 )
2017
3
Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms. ( 27997065 )
2017
4
DRD2 and ANKK1 genes associate with late-onset heroin dependence in men. ( 28854834 )
2017
5
Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese. ( 28692418 )
2017
6
Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs. ( 28473157 )
2017
7
A novel inhibitor of endocannabinoid catabolic enzymes sheds light on behind the scene interplay between chronic pain, analgesic tolerance, and heroin dependence. ( 27890603 )
2017
8
Association between dopamine D2 receptor gene polymorphisms and the risk of heroin dependence. ( 27819741 )
2016
9
Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. ( 27010727 )
2016
10
Influence of Duration of Heroin Dependence on Humoral Immunologic Indicators. ( 27610581 )
2016
11
Genome-Wide Association of Heroin Dependence in Han Chinese. ( 27936112 )
2016
12
Polymorphisms in the 5-hydroxytryptamine receptor 3B gene are associated with heroin dependence in the Chinese Han population. ( 27773795 )
2016
13
Heroin craving and its correlations with clinical outcome indicators in people with heroin dependence receiving methadone maintenance treatment. ( 26773990 )
2016
14
Association between serotonin transporter gene polymorphisms and heroin dependence: a meta-analytic study. ( 27942217 )
2016
15
Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. ( 27664554 )
2016
16
Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal. ( 26774004 )
2016
17
Evidence for the contribution of genetic variations in regulator of G protein signaling 9 to the genetic susceptibility of heroin dependence. ( 25591550 )
2015
18
QTc Prolongation in Veterans With Heroin Dependence on Methadone Maintenance Treatment. ( 26097838 )
2015
19
Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study. ( 25619110 )
2015
20
MalmAP Treatment Referral and Intervention Study (MATRIS)-effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. ( 26613636 )
2015
21
GABRB2 Haplotype Association with Heroin Dependence in Chinese Population. ( 26561861 )
2015
22
Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence. ( 25484035 )
2015
23
Association between variable number of tandem repeats (VNTR) polymorphism in the promoter region of monoamine oxidase A (MAOA) gene and susceptibility to heroin dependence. ( 26298506 )
2015
24
Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. ( 25781230 )
2015
25
Acknowledging Heroin Dependence as a Preventable Pediatric Chronic Medical Condition. ( 26163081 )
2015
26
The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients. ( 25640280 )
2015
27
Serum brain-derived neurotrophic factor levels and psychotic symptoms in heroin dependence. ( 26343470 )
2015
28
Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence. ( 25452049 )
2015
29
Single-nucleotide polymorphisms in dopamine receptor D1 are associated with heroin dependence but not impulsive behavior. ( 25966176 )
2015
30
Factors associated with one year retention to methadone maintenance treatment program among patients with heroin dependence in China. ( 24565169 )
2014
31
Excessive suicide mortality and risk factors for suicide among patients with heroin dependence. ( 25456334 )
2014
32
Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population. ( 24498053 )
2014
33
Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. ( 22500942 )
2014
34
The Evidence for the Contribution of the Autism Susceptibility Candidate 2 (AUTS2) Gene in Heroin Dependence Susceptibility. ( 25398668 )
2014
35
Gender sameness and difference in recovery from heroin dependence: A qualitative exploration. ( 24041800 )
2014
36
Prevalence of antisocial personality disorder among Chinese individuals receiving treatment for heroin dependence: a meta-analysis. ( 25477719 )
2014
37
Association analysis of GABRB3 promoter variants with heroin dependence. ( 25025424 )
2014
38
PTSD risk associated with a functional DRD2 polymorphism in heroin-dependent cases and controls is limited to amphetamine-dependent individuals. ( 23647975 )
2014
39
Chronic heroin dependence leading to adrenal insufficiency. ( 25221675 )
2014
40
DRD3 variation associates with early-onset heroin dependence, but not specific personality traits. ( 24398431 )
2014
41
Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence. ( 25048760 )
2014
42
[Association study of CNR1, GAD1 and BDNF polymorphisms with male heroin dependence in the Dai population in Yunnan]. ( 25252306 )
2014
43
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. ( 24725468 )
2014
44
Comparative gene expression profiling analysis of lymphoblastoid cells reveals neuron-specific enolase gene (ENO2) as a susceptibility gene of heroin dependence. ( 21995595 )
2014
45
Comparative study of the perceived quality of life of patients in treatment for cocaine and heroin dependence in Spain: differences by gender and time in treatment. ( 24712297 )
2014
46
Gender differences in prevalence and correlates of antisocial personality disorder among heroin dependent users in compulsory isolation treatment in China. ( 24342175 )
2014
47
The effect of heroin dependence on resumption of heroin self-administration in rats. ( 24613630 )
2014
48
Association of the GDNF gene with depression and heroin dependence, but not schizophrenia, in a Chinese population. ( 24022000 )
2013
49
Assessing the usefulness of health data linkage in obtaining adverse event data in a randomised controlled trial of oral and implant naltrexone in the treatment of heroin dependence. ( 23241479 )
2013
50
Pathways to heroin dependence: time to re-appraise self-medication. ( 23075121 )
2013

Variations for Heroin Dependence

Expression for Heroin Dependence

Search GEO for disease gene expression data for Heroin Dependence.

Pathways for Heroin Dependence

GO Terms for Heroin Dependence

Cellular components related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.43 OPRD1 OPRM1 SLC6A3
2 integral component of plasma membrane GO:0005887 9.43 DRD2 DRD4 GABRB2 OPRD1 OPRM1 SLC6A3
3 postsynapse GO:0098794 9.32 DRD4 OPRM1
4 dendrite membrane GO:0032590 9.16 OPRD1 OPRM1
5 axon terminus GO:0043679 8.8 DRD2 OPRD1 PDYN

Biological processes related to Heroin Dependence according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.7 DRD2 OPRM1 SLC6A3
2 neuropeptide signaling pathway GO:0007218 9.67 OPRD1 OPRM1 PDYN
3 chemical synaptic transmission GO:0007268 9.67 GABRB2 OPRD1 OPRM1 PDYN
4 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 OPRD1 OPRM1
5 response to nicotine GO:0035094 9.65 DRD2 SLC6A3
6 positive regulation of multicellular organism growth GO:0040018 9.64 DRD2 SLC6A3
7 response to morphine GO:0043278 9.64 DRD2 OPRM1
8 regulation of sensory perception of pain GO:0051930 9.63 OPRD1 OPRM1
9 locomotory behavior GO:0007626 9.63 DRD2 OPRM1 SLC6A3
10 response to amphetamine GO:0001975 9.62 DRD2 DRD4
11 eating behavior GO:0042755 9.62 OPRD1 OPRM1
12 arachidonic acid secretion GO:0050482 9.61 DRD2 DRD4
13 behavioral response to cocaine GO:0048148 9.61 DRD2 DRD4
14 dopamine receptor signaling pathway GO:0007212 9.6 DRD2 DRD4
15 response to iron ion GO:0010039 9.59 DRD2 SLC6A3
16 negative regulation of protein secretion GO:0050709 9.58 DRD2 DRD4
17 negative regulation of cAMP biosynthetic process GO:0030818 9.58 DRD4 OPRM1
18 dopamine metabolic process GO:0042417 9.57 DRD2 DRD4
19 sensory perception GO:0007600 9.56 OPRM1 PDYN
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.55 DRD2 DRD4
21 prepulse inhibition GO:0060134 9.54 DRD2 SLC6A3
22 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.51 DRD2 DRD4
23 regulation of dopamine metabolic process GO:0042053 9.48 DRD4 SLC6A3
24 adenohypophysis development GO:0021984 9.43 DRD2 SLC6A3
25 opioid receptor signaling pathway GO:0038003 9.4 OPRD1 OPRM1
26 response to cocaine GO:0042220 9.33 DRD2 OPRM1 SLC6A3
27 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.32 DRD2 DRD4
28 response to histamine GO:0034776 9.26 DRD2 DRD4
29 negative regulation of adenylate cyclase activity GO:0007194 9.13 DRD2 DRD4 OPRM1
30 behavioral response to ethanol GO:0048149 8.8 DRD2 DRD4 OPRM1
31 G-protein coupled receptor signaling pathway GO:0007186 10.03 DRD2 DRD4 OPRD1 OPRM1 PDYN

Molecular functions related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.67 DRD2 DRD4 OPRD1 OPRM1
2 neuropeptide binding GO:0042923 9.4 OPRD1 OPRM1
3 drug binding GO:0008144 9.33 DRD2 DRD4 SLC6A3
4 opioid receptor activity GO:0004985 9.32 OPRD1 OPRM1
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD2 DRD4
6 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD2 DRD4
7 dopamine binding GO:0035240 8.8 DRD2 DRD4 SLC6A3

Sources for Heroin Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....